New MS biosimilar PB018 faces first human test against ocrevus
NCT ID NCT07606521
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial will test PB018, a biosimilar to the MS drug Ocrevus, in 222 people with multiple sclerosis. The study compares how the body processes PB018 versus Ocrevus and checks for safety. Participants will receive either PB018 or Ocrevus, but neither they nor their doctors will know which one. The goal is to see if PB018 behaves similarly in the body, which could lead to a more affordable treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PB018 (a biosimilar to ocrelizumab)
- What this could lead to
- If successful, PB018 could offer a more affordable treatment option for multiple sclerosis, similar to Ocrevus.
- What could go wrong
- This is an early Phase 1 trial focused on drug levels and safety, not on effectiveness. The biosimilar may not work as well or have different side effects than Ocrevus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?